Retinoblastoma Global Clinical Trials Review, H1, 2014

Retinoblastoma Global Clinical Trials Review, H1, 2014 is a new pharma report announced by Reportstac. This report provides data on the Retinoblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinoblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Retinoblastoma.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

More details and table of contents at http://www.reportstack.com/product/153379/retinoblastoma-global-clinical-trials-review-h1-2014.htmlhttp://www.reportstack.com/product/153379/retinoblastoma-global-clinical-trials-review-h1-2014.html

Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2014

Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H1, 2014 is a new report announced by Reportstack. This report provides data on the Wilms’ Tumor (Nephroblastoma) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Wilms’ Tumor (Nephroblastoma). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Wilms’ Tumor (Nephroblastoma). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

More details and table of contents can be found by visiting http://www.reportstack.com/product/153383/wilms-tumor-nephroblastoma-global-clinical-trials-review-h1-2014.htmlhttp://www.reportstack.com/product/153383/wilms-tumor-nephroblastoma-global-clinical-trials-review-h1-2014.html

Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014

Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014 is a new pipeline review report announced by Reportstack. Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Squamous Non-Small Cell Lung Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Squamous Non-Small Cell Lung Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Squamous Non-Small Cell Lung Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

More details and table of contents can be found by visiting http://www.reportstack.com/product/153384/squamous-non-small-cell-lung-carcinoma-global-clinical-trials-review-h1-2014.htmlSquamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014 is a new pipeline review report announced by Reportstack. Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Squamous Non-Small Cell Lung Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Squamous Non-Small Cell Lung Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Squamous Non-Small Cell Lung Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies More details and table of contents can be found by visiting http://www.reportstack.com/product/153384/squamous-non-small-cell-lung-carcinoma-global-clinical-trials-review-h1-2014.html

Subependymal Giant Cell Astrocytoma Global Clinical Trials Review, H1, 2014

Subependymal Giant Cell Astrocytoma Global Clinical Trials Review, H1, 2014 is a new pipeline review report announced by Reportstack. This report provides data on the Subependymal Giant Cell Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Subependymal Giant Cell Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Subependymal Giant Cell Astrocytoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies.

More details about this report can be found at http://www.reportstack.com/product/153385/subependymal-giant-cell-astrocytoma-global-clinical-trials-review-h1-2014.html

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2014

 Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2014 is a new pipeline review report announced by Reportstack.

This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To Order this Report: http://www.reportstack.com/product/153278/retinitis-pigmentosa-retinitis-pipeline-review-h1-2014.html

Scope

• The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Retinitis Pigmentosa (Retinitis) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Retinitis Pigmentosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Retinitis Pigmentosa pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

QLT Inc. Sanofi Sun Pharmaceutical Industries Limited BioDiem Ltd ReGenX Biosciences, LLC ReNeuron Group plc R-Tech Ueno, Ltd. Acucela Inc. Neurotech Pharmaceuticals, Inc. Orphagen Pharmaceuticals, Inc. Grupo Ferrer Internacional, S.A. Stemedica Cell Technologies, Inc. Asklepios BioPharmaceutical, Inc. to-BBB technologies BV Dompe Farmaceutici S.p.A. DNAVEC Corporation Bikam Pharmaceuticals, Inc. Mimetogen Pharmaceuticals Inc. Genable Technologies Limited California Stem Cell, Inc. Amarantus Bioscience Holdings, Inc. GenSight Biologics

To order this report, please visit http://www.reportstack.com/product/153278/retinitis-pigmentosa-retinitis-pipeline-review-h1-2014.html